Last reviewed · How we verify
Other topical
At a glance
| Generic name | Other topical |
|---|---|
| Also known as | Standard topical therapy |
| Sponsor | LEO Pharma |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN) (PHASE2)
- Little NIRVANA for Pediatric Pain and Anxiety (NA)
- DaxibotulinumtoxinA for Blepharospasm (PHASE2)
- Glyceryl Trinitrate Gel Phonophoresis on Planter Fasciiatis (NA)
- Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)
- Combination of Oral and Topical Whitening Agents for Reducing Skin Pigmentation (NA)
- Counterpain PXM Versus Diclofenac Versus Piroxicam (PHASE3)
- A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Other topical CI brief — competitive landscape report
- Other topical updates RSS · CI watch RSS
- LEO Pharma portfolio CI